XBI
SPDR S&P Biotech ETF
SPDR S&P Biotech ETF historical holders
total: 1
Appaloosa Management SPDR S&P Biotech ETF transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2017 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2017 Q3
David Tepper has been an institutional investor in SPDR S&P Biotech ETF (XBI) since 2017 Q2. According to 2026 Q2 report, David Tepper doesn't hold any shares. The fund/company first acquired XBI in 2017 Q2, initially purchasing 330,000 shares. Since the initial investment, Appaloosa Management has made 1 more transaction in this position.
When did David Tepper exit their XBI position?
David Tepper no longer holds SPDR S&P Biotech ETF (XBI). They sold off their entire position in 2017 Q3, closing out an investment that began in 2017 Q2.
When did David Tepper first invest in XBI?
David Tepper first invested in SPDR S&P Biotech ETF (XBI) in 2017 Q2 at the reported quarter-end price of $77.18 per share, acquiring 330,000 shares in their initial purchase.
What is David Tepper's average cost basis for XBI?
Based on historical transaction data, David Tepper's estimated cost basis for SPDR S&P Biotech ETF (XBI) is approximately $77.18 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $77.18
- Weighted AVG sell price:
- $77.18
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.